November 26, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
Company
News Sectors
Automotive
Communications
Consumers
CSR
Electronics
Energy
Environment
Financial
Health & Med
Industrial
IT & Internet
Materials
Real Estate
Science & Research
Telecoms
Trade
Transportation
Departments
Annual Reports
Companies
News Alerts
News Search
Photo Gallery
Company Login
Japan Corporate News Network
About JCN
Privacy Policy
RSS  
Terms of Use
 
 
 

 Headline News

Nitto Denko Anti-fibrosis Drug Starts Phase-1b Dosing for Cirrhosis Patients in the US (Oct 10, 2014)
Nitto Denko Corporation (Nitto) announced the initiation of a phase-1b clinical study in the US started in September 2014, to administer a new anti-fibrosis drug in patients for the assessment of safety and efficacy. more info >>
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Mitsui & Co. has invested in "KIFMEC specific purpose company" which has been established in order to lease a hospital building to Kobe International Frontier Medical Center ("KIFMEC"). more info >>
ACN Newswire
 Press Release News

Eisai Launches Anticancer Agent Halaven as Company's First Product in Brazil (Nov 26, 2014)
Eisai Co., Ltd. announced today that its Brazil subsidiary Eisai Laboratorios Ltda. has launched the anticancer agent Halaven (eribulin mesylate) in the country. more info >>
Eisai Launches Antiepileptic Drug Fycompa in Hong Kong (Nov 21, 2014)
Eisai Co., Ltd. announced today that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has launched the AMPA receptor antagonist Fycompa (perampanel), a first-in-class antiepileptic drug (AED) discovered and developed in-house, in the region as an adjunctive treatment for partial-onset seizures with or without secondary generalized seizures in patients with epilepsy aged 12 years and older. more info >>
JCI Pharmaceutical Co., Ltd. Receives Approval from US FDA for Colloidal Iodine Formulation (Nov 20, 2014)
JCI Pharmaceutical Co., Ltd. has announced approval by the US FDA for its MN colloid iodine (C.I.M.N), a formulation utilizing a world-first technology for converting iodine into a colloidal state to make it absorbable into the body at a large doses. more info >>
Eisai's Ranking Significantly Increases in the Access to Medicine Index 2014 (Nov 17, 2014)
Eisai Co., Ltd. announced today that Eisai has been ranked 11th among the world's leading pharmaceutical companies in the Access to Medicine Index (ATM Index) 2014, representing a significant increase of four places from its previous ranking in 2012. more info >>
Lorcaserin Meets Primary Endpoint and Confirms Proof-Of-Concept as Potential Aid for Smoking Cessation in Investigational Phase II Clinical Study (Nov 4, 2014)
Eisai Co., Ltd. announced today that in a Phase II clinical study investigating the serotonin 2C receptor agonist lorcaserin hydrochloride as a potential aid for smoking cessation conducted by Arena Pharmaceuticals, Inc. and its U.S. subsidiary Eisai Inc., lorcaserin demonstrated a statistically significant increase in the study's primary endpoint of continuous quit rate compared to placebo, thus confirming proof-of-concept. more info >>
 Global Press Release

Eisai Launches Anticancer Agent Halaven as Company's First Product in Brazil (Nov 26, 2014)

Eisai Launches Antiepileptic Drug Fycompa in Hong Kong (Nov 21, 2014)

JCI Pharmaceutical Co., Ltd. Receives Approval from US FDA for Colloidal Iodine Formulation (Nov 20, 2014)

Eisai's Ranking Significantly Increases in the Access to Medicine Index 2014 (Nov 17, 2014)

Lorcaserin Meets Primary Endpoint and Confirms Proof-Of-Concept as Potential Aid for Smoking Cessation in Investigational Phase II Clinical Study (Nov 4, 2014)

JCN Network - Company Profiles - Company Listing
 
CSR Report Download
Most Popular
About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)